Fibrodysplasia ossificans progressiva - Pipeline Insight, 2021
This report can be delivered to the clients within 72 hours
DelveInsight’s, “Fibrodysplasia ossificans progressiva - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Fibrodysplasia ossificans progressiva pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Fibrodysplasia ossificans progressiva: Overview
Fibrodysplasia ossificans progressiva (FOP) is a very rare genetic connective tissue disorder characterized by the abnormal development of bone in areas of the body where bone is not normally present (heterotopic ossification), such as the ligaments, tendons, and skeletal muscles. Specifically, this disorder causes the body’s skeletal muscles and soft connective tissues to undergo a metamorphosis, essentially a transformation into bone, progressively locking joints in place and making movement difficult or impossible. Patients with FOP have malformed big toes that are present at birth (congenital). Other skeletal malformations may occur. The abnormal episodic development of bone at multiple soft tissue sites frequently leads to stiffness in affected areas, limited movement, and eventual ankylosis (fusion) of affected joints (neck, back, shoulders, elbows, hips knees, wrists, ankles, jaw – often in that order).
'Fibrodysplasia ossificans progressiva - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Fibrodysplasia ossificans progressiva pipeline landscape is provided which includes the disease overview and Fibrodysplasia ossificans progressiva treatment guidelines. The assessment part of the report embraces, in depth Fibrodysplasia ossificans progressiva commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fibrodysplasia ossificans progressiva collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Fibrodysplasia ossificans progressiva report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Fibrodysplasia ossificans progressiva Emerging Drugs
Further product details are provided in the report……..
Fibrodysplasia ossificans progressiva: Therapeutic Assessment
This segment of the report provides insights about the different Fibrodysplasia ossificans progressiva drugs segregated based on following parameters that define the scope of the report, such as:
Fibrodysplasia ossificans progressiva: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fibrodysplasia ossificans progressiva therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fibrodysplasia ossificans progressiva drugs.
Fibrodysplasia ossificans progressiva Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Fibrodysplasia ossificans progressiva - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Fibrodysplasia ossificans progressiva pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Fibrodysplasia ossificans progressiva: Overview
Fibrodysplasia ossificans progressiva (FOP) is a very rare genetic connective tissue disorder characterized by the abnormal development of bone in areas of the body where bone is not normally present (heterotopic ossification), such as the ligaments, tendons, and skeletal muscles. Specifically, this disorder causes the body’s skeletal muscles and soft connective tissues to undergo a metamorphosis, essentially a transformation into bone, progressively locking joints in place and making movement difficult or impossible. Patients with FOP have malformed big toes that are present at birth (congenital). Other skeletal malformations may occur. The abnormal episodic development of bone at multiple soft tissue sites frequently leads to stiffness in affected areas, limited movement, and eventual ankylosis (fusion) of affected joints (neck, back, shoulders, elbows, hips knees, wrists, ankles, jaw – often in that order).
'Fibrodysplasia ossificans progressiva - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Fibrodysplasia ossificans progressiva pipeline landscape is provided which includes the disease overview and Fibrodysplasia ossificans progressiva treatment guidelines. The assessment part of the report embraces, in depth Fibrodysplasia ossificans progressiva commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fibrodysplasia ossificans progressiva collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Fibrodysplasia ossificans progressiva R&D. The therapies under development are focused on novel approaches to treat/improve Fibrodysplasia ossificans progressiva.
This segment of the Fibrodysplasia ossificans progressiva report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Fibrodysplasia ossificans progressiva Emerging Drugs
- Palovarotene: Ipsen
- BLU-782: Blueprint Medicines
Further product details are provided in the report……..
Fibrodysplasia ossificans progressiva: Therapeutic Assessment
This segment of the report provides insights about the different Fibrodysplasia ossificans progressiva drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Fibrodysplasia ossificans progressiva
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Fibrodysplasia ossificans progressiva: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fibrodysplasia ossificans progressiva therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fibrodysplasia ossificans progressiva drugs.
Fibrodysplasia ossificans progressiva Report Insights
- Fibrodysplasia ossificans progressiva Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Fibrodysplasia ossificans progressiva drugs?
- How many Fibrodysplasia ossificans progressiva drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fibrodysplasia ossificans progressiva?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Fibrodysplasia ossificans progressiva therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Fibrodysplasia ossificans progressiva and their status?
- What are the key designations that have been granted to the emerging drugs?
- Ipsen
- Blueprint Medicines
- Regeneron Pharmaceuticals
- Daiichi Sankyo, Inc.
- AstraZeneca
- Incyte Corporation
- Keros Therapeutics
- BioCryst Pharmaceuticals
- Palovarotene
- BLU 782
- REGN2477
- DS-6016a
- AZD0530
- INCB 000928
- KER 047
- BCX 9250
- BCX 9499
Introduction
Executive Summary
Fibrodysplasia ossificans progressiva: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Fibrodysplasia ossificans progressiva – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Palovarotene: Ipsen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
BLU 782: Blueprint Medicines
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
DS 6016: Daiichi Sankyo
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Fibrodysplasia ossificans progressiva Key Companies
Fibrodysplasia ossificans progressiva Key Products
Fibrodysplasia ossificans progressiva- Unmet Needs
Fibrodysplasia ossificans progressiva- Market Drivers and Barriers
Fibrodysplasia ossificans progressiva- Future Perspectives and Conclusion
Fibrodysplasia ossificans progressiva Analyst Views
Fibrodysplasia ossificans progressiva Key Companies
Appendix
Executive Summary
Fibrodysplasia ossificans progressiva: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Fibrodysplasia ossificans progressiva – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Palovarotene: Ipsen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
BLU 782: Blueprint Medicines
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
DS 6016: Daiichi Sankyo
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Fibrodysplasia ossificans progressiva Key Companies
Fibrodysplasia ossificans progressiva Key Products
Fibrodysplasia ossificans progressiva- Unmet Needs
Fibrodysplasia ossificans progressiva- Market Drivers and Barriers
Fibrodysplasia ossificans progressiva- Future Perspectives and Conclusion
Fibrodysplasia ossificans progressiva Analyst Views
Fibrodysplasia ossificans progressiva Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Fibrodysplasia ossificans progressiva
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Fibrodysplasia ossificans progressiva
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Fibrodysplasia ossificans progressiva
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Fibrodysplasia ossificans progressiva
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
